Maze Therapeutics, Inc. (NASDAQ:MAZE) Sees Significant Growth in Short Interest

Maze Therapeutics, Inc. (NASDAQ:MAZE) was the recipient of a significant increase in short interest in February. As of February 13th, there was short interest totaling 3,356,466 shares, an increase of 22.4% from the January 29th total of 2,741,979 shares. Based on an average trading volume of 608,007 shares, the days-to-cover ratio is presently 5.5 days. Approximately 7.0% of the shares of the stock are short sold. Approximately 7.0% of the shares of the stock are short sold. Based on an average trading volume of 608,007 shares, the days-to-cover ratio is presently 5.5 days.

Insider Buying and Selling at Maze Therapeutics

In related news, CMO Harold Bernstein sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $46.02, for a total value of $690,300.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Amy Bachrodt sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00. Following the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at $596,908.60. The trade was a 27.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 200,000 shares of company stock valued at $8,254,792.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC grew its holdings in shares of Maze Therapeutics by 318.0% during the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after acquiring an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. grew its stake in Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after purchasing an additional 915,342 shares in the last quarter. Marshall Wace LLP increased its position in Maze Therapeutics by 3,868.5% in the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after purchasing an additional 758,104 shares during the last quarter. Caligan Partners LP acquired a new position in Maze Therapeutics in the 4th quarter worth about $22,794,000. Finally, ArrowMark Colorado Holdings LLC purchased a new stake in shares of Maze Therapeutics during the 3rd quarter worth about $14,135,000.

Maze Therapeutics Stock Down 3.1%

Shares of MAZE traded down $1.43 during trading hours on Tuesday, reaching $44.18. The company’s stock had a trading volume of 289,898 shares, compared to its average volume of 438,088. The company has a 50 day moving average of $43.66 and a two-hundred day moving average of $33.73. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of -2.11 and a beta of 4.46. Maze Therapeutics has a 1-year low of $6.71 and a 1-year high of $49.25.

Analyst Ratings Changes

MAZE has been the subject of a number of recent research reports. Wells Fargo & Company started coverage on Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective for the company. Wedbush boosted their target price on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Maze Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $46.86.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.